The Global Scleroderma Therapeutics Market Size accounted for USD 2,912 Million in 2021 and is estimated to achieve a market size of USD 5,018 Million by 2030 growing at a CAGR of 6.4% from 2022 to 2030. The increased incidence and screening rates of scleroderma are the key drivers of the scleroderma therapeutics market value. Moreover, the existence of a well-defined regulatory framework that supports the development of effective medicines, as well as increased frequencies of genetic abnormalities coupled with significant changes in the environment, are projected to be major elements propelling the scleroderma therapeutics market growth.

Scleroderma Therapeutics Market Report Key Highlights

• Global scleroderma therapeutics market revenue is expected to expand by USD 5,018 million by 2030, with a 6.4% CAGR from 2022 to 2030
• North America scleroderma therapeutics market share accounting for around 37% of the total market in 2021
• According to research, systemic sclerosis affects approximately 30 people per million people each year, with an estimated 125,000 active cases in the United States and maybe 2.5 million worldwide
• According to Scleroderma & Raynaud's UK, approximately 19,000 persons were diagnosed with Scleroderma in the UK in 2018
• Among drug class, immunosuppressors segment will account for more than 60% of overall market share in 2021
• By indications, systemic segment accounted 65% revenue share in 2021

Scleroderma is an autoimmune rheumatic condition that causes the skin and connective tissues to get chronically hardened and tightened. However, it includes the overproduction of collagen. The exact cause of Scleroderma is not known. Inner bodies such as blood vessels, heart, lungs, belly, and kidneys may suffer harm. Scleroderma incidents in females are four times higher than in males. In addition, starting between 30 and 50 years is more frequent.

The elevated effect on scleroderma diagnostics and on the therapy industry of divers is the increased incidence of scleroderma and the increased incidence of genetic mutations combined with dramatic environmental modifications. The incidence of systemic scleroderma is approximately 35 instances per 1 million adults according to international reports from Japan and Britain. Four times more women than males are susceptible to systemic scleroderma. Furthermore, this market is anticipated to serve as future growth possibilities if high unsatisfied medical demands and the subsequent introduction of fresh products are met.

 Global Scleroderma Therapeutics Market Dynamics

Market Drivers

• Growing incidence of scleroderma
• Increasing pharmaceutical companies' focus on developing novel drugs
• Rising rates of genetic mutations, as well as extreme environmental changes
• Advancing clinical trials and immunosuppressant efficacy

Market Restraints

• A lack of well-defined regulations
• Reimbursement Issues in many regions

Market Opportunities

• Increasing research and development activities
• Expansion of the pharmaceutical pipeline

Scleroderma Therapeutics Market Report Coverage

Market	Scleroderma Therapeutics Market
Scleroderma Therapeutics Market Size 2021	USD 2,912 Million
Scleroderma Therapeutics Market Forecast 2030	USD 5,018 Million
Scleroderma Therapeutics Market CAGR During 2022 - 2030	6.4%
Scleroderma Therapeutics Market Analysis Period	2018 - 2030
Scleroderma Therapeutics Market Base Year	2021
Scleroderma Therapeutics Market Forecast Data	2022 - 2030
Segments Covered	By Drug Class, By Indication, And By Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Active Biotech AB, Daval International Ltd., BioLineRx, Ltd., Corbus pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Angion Biomedica Corp., Fibrocell Science, Inc., Bayer AG, Bristol-Myers Squibb Company, Allergan, Inc., and Dynavax Technologies Corporation.
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Scleroderma Therapeutics Market Insights

The scleroderma therapeutics market is motivated primarily by the labeling of drugs for its symptoms such as rheumatoid arthritis that are approved. The absence of curative therapies and the elevated incidence of off-label drug use are factors that stimulate interest in the markets for rare diseases.

The development of targeted biologics and tiny molecular combination therapies is anticipated to be fuel the scleroderma therapeutics market trend. The market is also anticipated to be driven by increased scleroderma and the increasing incidence of genetic mutations combined with dramatic environmental modifications.

Furthermore, growing available revenue, allowing for increased expenditure ability and the existence of a well-defined legislative structure to support efficient therapy development in advanced region fuel market development. In addition, the development of premium curatives undergoing clinical development will increase market growth over the forecast era. Additional approvals will also enhance the development of current therapy alternatives.

This disease involves a broad variety of drug classes prescribed for first and second-line treatment. The disease is correlated with comorbidity. Among the signs, the highest possible sales were achieved with pulmonary arterial hypertension (PAH). More than one drug class and several branded drugs form part of the drugs for this comorbidity. In addition, both authorized medicines are used to target PAH in this market, namely bosentan, and iloprost. Increased Scleroderma incidence mainly drives development on the market. Scleroderma is a disease of long duration that demands a daily dose of medicines. In addition, the scleroderma diagnostics and therapeutics market is projected to raise awareness of preventive health care and boost disposable income among the population. In addition, strict public regulations, adverse drug effects, elevated healthcare costs, and Scleroderma diagnostic tests are key obstacles to the development of the industry. Ongoing R&D is expected to generate fresh possibilities during the forecast era in scleroderma diagnosis and therapeutics.

Scleroderma Therapeutics Market Segmentation           

The worldwide scleroderma therapeutics market segmentation is based on the drug class, indication, and geography.

Scleroderma Therapeutics Market By Drug Class

• Immunosuppressors
• Analgesic
• Phosphodiesterase 5 Inhibitors - PHA
• Endothelin Receptor Antagonists
• Calcium Channel Blockers
• Prostacyclin Analogues
• Others

According to the scleroderma therapeutics industry analysis, the immunosuppressors segment will be the most important in the market. Immunosuppressants are of prominence because they include several biological products from well-known players like Roche. Small molecule immunosuppressants and biologics are an increasing sector with several scleroderma pipeline medicines. In the forecast period classified under "other drug classes," new treatments, including Lenabasum and Ofev, are anticipated. PDE-5 drug class market inhibitors face headwinds as a result of Revatio's patent expiry which decreases income. ERAs continue to be focused as the drug class mainly includes branded therapies and is therefore highly effective in their use in the therapy of the indication.

Scleroderma Therapeutics Market By Indication

• Systemic
• Localized

According to the scleroderma therapeutics market forecast, the systemic segment is projected to lead the market in the coming years. Systemic scleroderma symptoms and conditions range from interstitial pulmonary illness to arterial pulmonary hypertension. Most systemic symptoms are caused by the use of expensive immunosuppressants.

Local scleroderma is presently low but is anticipated to develop during the forecast period, with Fibrocell's anticipated launch of first-class FCX-013 treatment. Fibrocell's FCX-013 retains the designation of orphan drug and quick track, which would be the first localized scleroderma gene treatment if approved. This therapy is intended to stop fibrosis in the early phases. The first oral treatment of Lenabasum with the elevated curative capacity for diffuse systemic scleratic cutaneous diseases associated with an elevated co-morbidity burden is Corbus Pharmaceuticals.

Scleroderma Therapeutics Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Latin America

• Mexico
• Brazil
• Rest of Latin America

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

The Middle East & Africa (MEA)

• Gulf Cooperation Council (GCC)
• South Africa
• Rest of the Middle East & Africa